ArticleEsophagus : official journal of the Japan Esophageal Society2025

Safety and short-term outcomes of adjuvant nivolumab therapy at 480 mg dose every four weeks in resected esophageal cancer: a prospective cohort study.

Takahito Sugase et al.PubMed ↗Publisher ↗

No numbers read from the abstract.